---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-325375"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:59:25.027324+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics reports Q3 2021 net loss of $11.4M, cash $201.8M, and business development strategy

## Summary
- Cash and equivalents $201.8M as of Sept 30, 2021; net loss $11.4M ($0.17 per share) vs $16.4M ($0.28) in Q3 2020.
- Revenue zero vs $6.9M in Q3 2020; R&D expenses down to $4.9M from $15.9M due to OV101 wind-down and soticlestat termination.
- Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet enrolling; Ovid eligible for up to 20% royalties on global sales.
- Ovid plans to pursue business development for precision therapeutics; targets IND submission for OV329 in 2022.
- Kevin Fitzgerald, Ph.D., former Alnylam CSO, appointed to Board of Directors.

## SEC filing metadata
- accession: 0001193125-21-325375
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000119312521325375/0001193125-21-325375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000119312521325375/d245103d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-325375
- JSON: https://secwatch.observer/filing/0001193125-21-325375.json
- Plain text: https://secwatch.observer/filing/0001193125-21-325375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.